VELTIS
LIVE

Serial Number

99250298

Owner

Sartorius Albumedix Limited

Attorney

Russell C. Pangborn

Filing Date

Jun 24, 2025

Add to watchlist:

No watchlists yet
View on USPTO

VELTIS Trademark

Serial Number: 99250298

VELTIS is a trademark filed by Sartorius Albumedix Limited on June 24, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Sartorius Albumedix Limited (8 trademarks)

HQ, Mabel Street

Entity Type: 98

Trademark Details

Filing Date

June 24, 2025

Registration Date

Not Registered

Published for Opposition

September 15, 2026

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, urinary, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders; Reagents for medical pharmaceutical use, namely, for the stabilization, solubilization and preservation of therapeutic preparations and vaccines; Reagents for medical use; Diagnostic reagents for medical use; Proteins for pharmaceutical and medical purposes, namely, human and synthetic proteins, therapeutic proteins, recombinant albumin, human serum albumin and recombinant human albumin for use as cellular absorption, enzyme stabilizers and anti-coagulant agents for medical laboratory use; Albumin for pharmaceutical and medical purposes, namely, recombinant human albumin sold as an integral component of a vaccine and pharmaceuticals for the treatment of viral, metabolic, endocrine, urinary, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders; Recombinant albumin for use as a reagent for medical purposes; Diagnostic contrast agents for medical imaging

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 9, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 21, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 20, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 20, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 20, 2026 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 6, 2026 GNFN
FINAL REFUSAL E-MAILED
Jun 6, 2026 GNFR
FINAL REFUSAL WRITTEN
Jun 6, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 6, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 6, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 6, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 11, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 11, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 21, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 21, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 21, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 13, 2025 DOCK
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Aug 7, 2025 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 7, 2025 PARI
APPLICATION FILING RECEIPT MAILED
Jun 24, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 24, 2025 NWOS
NEW APPLICATION ENTERED
Jun 24, 2025 NWAP